From June 9, 2022 to June 30, 2022, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for CNY 0 million under the buyback announced on June 10, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.53 CNY | -0.38% |
|
-7.14% | -13.40% |
27/05 | ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets | MT |
07/05 | China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.40% | 136.1Cr | |
+55.32% | 82TCr | |
-6.75% | 35TCr | |
+13.56% | 31TCr | |
+10.68% | 30TCr | |
+16.57% | 24TCr | |
+2.04% | 22TCr | |
+13.31% | 22TCr | |
+8.48% | 17TCr | |
-2.81% | 16TCr |
- Stock Market
- Equities
- 603567 Stock
- News Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.